KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Charles River Laboratories International (CRL) Equity Ratio (2016 - 2025)

Charles River Laboratories International has reported Equity Ratio over the past 17 years, most recently at 0.44 for Q4 2025.

  • For Q4 2025, Equity Ratio fell 3.38% year-over-year to 0.44; the TTM value through Dec 2025 reached 0.44, down 3.38%, while the annual FY2025 figure was 0.44, 3.38% down from the prior year.
  • Equity Ratio for Q4 2025 was 0.44 at Charles River Laboratories International, down from 0.45 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.47 in Q3 2024 and troughed at 0.34 in Q3 2021.
  • A 5-year average of 0.41 and a median of 0.42 in 2023 define the central range for Equity Ratio.
  • Biggest five-year swings in Equity Ratio: decreased 6.3% in 2021 and later rose 22.05% in 2023.
  • Year by year, Equity Ratio stood at 0.36 in 2021, then increased by 8.48% to 0.39 in 2022, then grew by 12.11% to 0.44 in 2023, then increased by 4.6% to 0.46 in 2024, then dropped by 3.38% to 0.44 in 2025.
  • Business Quant data shows Equity Ratio for CRL at 0.44 in Q4 2025, 0.45 in Q3 2025, and 0.44 in Q2 2025.